-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Sign up for news updates
WCLC News
-
Additional ADAURA Analyses Help Support the Benefit of Adjuvant Osimertinib in Patients With Resected EGFR-Mutated NSCLC
The randomized phase III ADAURA trial stirred up considerable excitement last year when results from an unplanned interim analysis revealed an 80% reduction in the risk of disease recurrence or death with use of adjuvant osimertinib in comparison with placebo among patients with stage IB to IIIA NSCLC, far exceeding expectations for the global trial.1…
-
Practice-Changing Initiatives Benefit the Medical Team, Patients
The social and emotional needs of patients are increasingly being recognized as equally important to their physical needs, and use of multidisciplinary teams is helping to bridge the gaps between clinical and psychosocial care. The Education Session “Practice Changing Initiatives” (ES11) addressed exciting initiatives to move the field forward while helping patients become better advocates…
-
Addressing Lung Cancer Screening Disparities in the LGBT Community
Historically, sexual minorities have been underserved in the healthcare setting. Members of this patient population may be less likely to receive optimal care, especially when it comes to preventive care such as lung cancer screening—a topic that was discussed during the Mini Oral Abstract Session “MA04: Health Policy and the Real World.” The older (between…
-
Translating Early Research to Adapt CAR T-Cell Therapy to Solid Tumors
Although the initial research into adoptive T-cell therapy for solid tumors was related to tumor-infiltrating lymphocytes, there is a growing interest in the use of adoptive T-cell therapy for the treatment of these diseases. As part of Friday’s Plenary session “PL03: Bench to Bedside (Immunology),” Prasad S. Adusumilli, MD, FACS, attending and deputy chief of…
-
Mobocertinib May Offer Effective, Safe Treatment in NSCLC with EGFR Exon 20 Insertion Mutation
With no approved treatments for advanced NSCLC with EGFR exon 20 insertion mutations, treatment is mainly limited to chemotherapy, as these cancers don’t respond to traditional tyrosine kinase inhibitors (TKIs). But previously treated patients with this rare subtype responded to mobocertinib, with a manageable safety profile, in a phase I/II trial discussed during (OA04: New…
-
More Data Needed on Benefit of Adaptive Radiation Approaches in Locally-Advanced NSCLC
The results of one phase II study looking at PET/CT-guided adaptive radiation therapy and one PET boost trial in locally advanced NSCLC were presented in an Oral Abstract Session (OA2). Previously published, long-term results of the ROTG 0617 trial showed that high-dose (74 Gy given in 2 Gy daily fractions that prolonged overall treatment time)…
-
Study Identifies Lung Cancer Areas of Improvement Across Asia-Pacific Region
Lung cancer prevention and treatment remains a challenge across the Asia-Pacific region, and each country has areas where they could improve, according to a study presented during the Day 2 mini oral session, “MA04: Health Policy and the Real World.” Lung cancer is the leading cause of cancer mortality in the Asia-Pacific region accounting for…
-
Several Studies Assess the Fallout From the COVID-19 Pandemic in Patients With Lung Cancer
The COVID-19 pandemic has undoubtedly altered patient care as countries have locked down to prevent spread of the virus and shifted resources to accommodate surging caseloads. It has also taken a considerable emotional toll on vulnerable individuals, particularly patients with cancer, given fears about contracting the virus and concerns about disruptions in care. Several researchers…
-
Redefining Good Quality Resections in NSCLC
Curative-intent resections for NSCLC often fail. Approximately 20% to 40% of patients with lung cancer who undergo curative-intent resection, experience a relapse, and die within 4 years. One key factor is the quality of the surgery, although there are no universal benchmarks of good quality resection, according to Raymond U. Osarogiagbon, MD, of the Thoracic…
-
Examining Value and Access in Lung Cancer Care, From Screening to Treatment
Appropriate and swift diagnosis and treatment are crucial for patients with lung cancer but can be elusive for many due to cost, healthcare disparities, and other barriers. Factors such as age, gender, and ethnicity can affect not only access to screening and care but also disease outcomes, as can the economic resources and quality of…
View ILCN Archives
Provider Resources
Popular Articles